Skye Bioscience stock analysis
Want to see SKYE full AI Analyst Report?
Skye Bioscience (SKYE) Stock Price & Analysis
SKYE Stock Chart & Stats
- Day’s Range
- $0.98 - $1.05
- 52-Week Range
- $0.50 - $11.04
- Previous Close
- $1.00
- Volume
- N/A
- Average Volume (3M)
- 89.86K
- Market Cap
- $4.56M
- Enterprise Value
- $3.27M
- Total Cash (Recent Filing)
- $4.82M
- Total Debt (Recent Filing)
- $9,452
- Price to Earnings (P/E)
- ―
- Beta
- 3.75
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Reported Leverage
Reported debt is only about $9K against $1.36M of TTM equity, limiting direct interest and leverage pressure in the near term. This gives the company some balance-sheet flexibility while it funds development, although it does not offset severe cash burn.
Expanded Therapeutic Pipeline
Combining with Redx would broaden Skye beyond its current metabolic focus into fibrotic disease, while the proposed Fibrx platform includes a Phase 2 lead asset and broader pipeline. If completed, this could improve program diversification and milestone potential.
Secured External Funding
The proposed financing package would provide substantial capital for clinical development and key milestones through 2029. That funding could reduce near-term financing pressure and support execution of the combined company’s pipeline, although operations remain externally funded.
Bears Say
Pre-Revenue Losses
Zero revenue and large recurring losses show the company has not yet commercialized a product or established an operating earnings base. Losses rose from about $26.6M in 2024 to $55.9M in 2025 and remained elevated TTM, leaving profitability dependent on successful development.
Persistent Cash Burn
Operating and free cash flow remain negative in every period, with TTM burn around $30.6M. Because operations are not self-funding, continued clinical development and corporate activity depend heavily on external capital, making liquidity and financing execution central to the outlook.
Nasdaq Compliance Risk
Negative stockholders’ equity of $497,307 at June 30, 2026 breached Nasdaq’s $2.5M requirement and creates a continuing compliance overhang. Remediation efforts and possible delisting could disrupt exchange access and complicate the Redx transaction and future financing.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
What is Skye Bioscience’s market cap?
When is Skye Bioscience’s upcoming earnings report date?
How were Skye Bioscience’s earnings last quarter?
Is Skye Bioscience overvalued?
Does Skye Bioscience pay dividends?
What is Skye Bioscience’s EPS estimate?
How many shares outstanding does Skye Bioscience have?
What happened to Skye Bioscience’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Skye Bioscience?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Skye Bioscience
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Punit Dhillon
- Employees
- 2
- Website
- skyebioscience.com
- Address
- 11250 El Camino Real, San Diego, CA, 92130, US
Skye Bioscience (SKYE) Earnings & Revenues
SKYE Earnings Call
Earnings Call SentimentNeutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.
View all SKYE earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 2 | 0 | 10 |












